

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

RETIREMENT OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”) announces that Ms. Li Mingqin (“**Ms. Li**”) has retired as an executive director of the Company at the conclusion of the annual general meeting of the Company held on 5 June 2024 (the “**AGM**”). Ms. Li did not offer herself for re-election at the AGM as she has reached the retirement age. Ms. Li has also ceased to be a member of the environmental, social and governance committee of the Company and resigned from all positions with the Company and its subsidiaries.

Ms. Li has confirmed that she has no disagreement with the Board and that there is no matter relating to her retirement which needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Ms. Li for her valuable contribution to the Company during her tenure of office.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 5 June 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.